Genetic testing and VWF:GP1bM activity by treatment group
| . | Total N = 20 . | rVWF + TXA n = 10 . | rVWF n = 10 . |
|---|---|---|---|
| Baseline VWF:GP1bM available | 12 (60) | 8 (80) | 4 (40) |
| VWF:GP1bM, IU/dL | 0.45 (0.23-0.64) | 0.48 (0.23-0.64) | 0.39 (0.23-0.48) |
| NGS: VWF available | 11 (55) | 6 (60) | 5 (50) |
| p.D1472H polymorphism∗ | 1 | 1 | 0 |
| Pathogenetic variant | 2 | 2 | 0 |
| Variant of unknown significance | 4 | 2 | 2 |
| . | Total N = 20 . | rVWF + TXA n = 10 . | rVWF n = 10 . |
|---|---|---|---|
| Baseline VWF:GP1bM available | 12 (60) | 8 (80) | 4 (40) |
| VWF:GP1bM, IU/dL | 0.45 (0.23-0.64) | 0.48 (0.23-0.64) | 0.39 (0.23-0.48) |
| NGS: VWF available | 11 (55) | 6 (60) | 5 (50) |
| p.D1472H polymorphism∗ | 1 | 1 | 0 |
| Pathogenetic variant | 2 | 2 | 0 |
| Variant of unknown significance | 4 | 2 | 2 |
Available NGS results and lowest recorded VWF:GP1bM activity levels outside of pregnancy. These tests were not conducted as part of the study protocol but were obtained from clinical records.
NGS, next-generation sequencing; VWF:GP1bM, von Willebrand factor:GP1bM activity.
One participant had a p.D1472H polymorphism in conjunction with a separate pathogenic VWF variant.